You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY23 is not expected to be complete until September, 2024.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Aberration-correcting Topologically Optimized Metasurface (ATOM)

    SBC: PHYSICAL SCIENCES INC.            Topic: HR001119S003524

    Metalenses, with their ability to arbitrarily control the amplitude and phase of light across a band of wavelengths, have the potential to disrupt imaging and communication systems which rely on traditional lenses to focus, collimate, and otherwise manipulate optical signals, and are under increasing pressure to operate with reduced size and weight. We propose to design, develop, and demonstrate a ...

    STTR Phase I 2020 Department of DefenseDefense Advanced Research Projects Agency
  2. A cell-free, high-throughput screening service for accelerated GPCR ligand discovery

    SBC: KXT BIO INC.            Topic: 300

    PROJECT SUMMARY The proposed Phase I STTR project is a partnership between a biotechnology company KXTbioIncand the University of North Carolina at Chapel Hill to develop an innovative high throughput screening service for identifying new drug candidates that act via G protein coupled receptorsGPCRsThis large protein superfamily has been the most successful source of therapeutic targetsaccounting ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  3. Administrative Supplement to restore fee funds

    SBC: AMERICAN LIFE SCIENCE PHARMACEUTICALS, INC.            Topic: NINDS

    Project Summary Traumatic brain injuryTBIcauses detrimental behavioral dysfunctions and brain neurodegeneration butunfortunatelythere currently is no effective pharmaceutical TBI treatmentThe underlying PhaseSTTR grant is to develop a new class of TBI drugs that inhibit the protease cathepsin BGenetically deleting the cathepsin B gene in mice results in substantial behavioral and pathology improve ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  4. Advancing Formulation of STING agonist for Universal Flu Vaccine

    SBC: IMMvention Therapeutix, Inc.            Topic: NIAID

    Summary Influenza virusa member of the orthomyxovirus familyhas three different types that infect humansABand CTypes A and B produce annual epidemicsand type A influenzawhich resides asymptomatically in birdscan cause pandemic infections in humansIn addition to common flu like symptomse gfeverchillsmalaisemuscle painin susceptible populations influenza can induce potentially fatal secondary compli ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  5. A Genes-to-Molecules Platform for Expanding Natural Product Diversity

    SBC: Lassogen, Inc.            Topic: NCCIH

    Project Summary Natural products (NPs) and derivatives thereof provide a rich source of chemical matter for drug discovery and development. Over the past 30 years, NP-derived drugs have accounted for more than 35% of FDA approvals. Despite their demonstrated importance, development of new NPs has slowed over the past 15 years due to the lack of efficient methods for discovery, production, and opti ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  6. A GIP Companion Drug for Enhancing Metabolic Benefits of Long-Acting GLP-1

    SBC: VELUM INC            Topic: NIA

    There is a world wide twin epidemic of obesity and TypeDiabetesT Dwith an urgent need to find effective new drug treatments for inducing weight lossStable derivatives of the endogenous glucoregulatory hormoneglucagon like peptideGLPare in clinical use for the treatment of T D but are of equally great interest as an emerging treatment of obesity and of age related neurodegenerative conditions inclu ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  7. Amelioration of rhinovirus induced asthma exacerbations by serpin B1

    SBC: SERPLUS TECHNOLOGY LLC            Topic: NIAID

    PROJECT SUMMARY Asthma exacerbations are a major cause of ER visits and hospitalizations with annual direct costs of approximately $billionyear in the USAViral infectionsin particular rhinoviralRVinfectionsare a major precipitant of asthma exacerbations in allergic asthmaticsAs there are overRV serotypes andfor nowno RV vaccinenovel strategies to inhibit RV induced airway inflammation are needed t ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  8. A Mobile Tai Chi Platform for Fall Prevention in Older Adults

    SBC: BIOSENSICS LLC            Topic: NIA

    Project Summary The overall goal of the proposed work is to develop a platform capable of delivering and monitoring adherenceproficiencyand safety of a home based simplified Tai Chi intervention for older adultsDuring Phase I of this Fast Track STTR project we will further develop a novel approach to assessing Tai Chi performance adherenceproficiencyand safety based on wearable sensor dataMetrics ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  9. A momentum-enabled treadling methodology to improve gait and enhance mobility in patients with peripheral arterial disease

    SBC: TREADWELL CORPORATION            Topic: NIA

    Project SummaryA significant cause of mobility impairment in the elderly is peripheral arterial diseasePADPAD results in significant functional declinereduced walking speed and distanceand lower physical activity levelsresulting in a loss of independence and impaired quality of lifeThe most effective therapy for PAD is rigorous exercisee gwalkingHowevermost PAD patients will not participate in sup ...

    STTR Phase I 2018 Department of Health and Human ServicesNational Institutes of Health
  10. A new generation, enhanced, corneal-birefringence-independent retinalscanning device for pediatric vision disorders using polarization modulation

    SBC: REBISCAN, Inc.            Topic: N

    Project Summary/Abstract !Amblyopia is vision loss caused by neglect of a structurally normal eye due to strabismus, asymmetric refraction (anisometropia), or deprivation. It is irreversible if not treated by age 7, but half of all patients in the U.S. are undetected and untreated until after it is too late, making it the leading cause of preventable vision loss. Rebion (Rebiscan, Inc) has develop ...

    STTR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government